Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oruka Therapeutics, Inc.ABIO · Entity 3781 | Director · Chairman of the Board | January 30, 2024 | January 31, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oruka Therapeutics, Inc.
Report date January 30, 2024 · Filed January 31, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.64 · Expires 2034-01-30 | Direct | 6,000 |
Reported balance
After 2024-01-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-30 · Grant · Acquired 6,000 · Balance 6,000 F1: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 30, 2024, subject to the Reporting Person continuing to provide Continuous Service (as defined in the 2020 Equity Incentive Plan) through such date. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested. |
| Common StockSEC Table I · non-derivative | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2024-01-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 50,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 30, 2024, subject to the Reporting Person continuing to provide Continuous Service (as defined in the 2020 Equity Incentive Plan) through such date. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALPINE IMMUNE SCIENCES, INC.
Report date May 20, 2024 · Filed May 20, 2024
Section 16 reporting ended · disclosed 2024-05-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Robert E. Conway Rev Trust and Carolyn J. Conway Rev Trust | 0 |
Reported balance
After 2024-05-20 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-05-20 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2: (Continued from Footnote 1) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.96 · Expires 2025-07-16 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-05-20 · Disposition to issuer · Disposed 2,868 · Balance 0 F3: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F6: (Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F4: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.08 · Expires 2026-09-12 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-05-20 · Disposition to issuer · Disposed 3,075 · Balance 0 F3: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F6: (Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F4: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.12 · Expires 2025-09-11 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-05-20 · Disposition to issuer · Disposed 1,912 · Balance 0 F3: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F6: (Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F4: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.31 · Expires 2028-01-01 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-05-20 · Disposition to issuer · Disposed 7,650 · Balance 0 F3: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F6: (Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F4: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.09 · Expires 2029-01-01 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-05-20 · Disposition to issuer · Disposed 7,650 · Balance 0 F3: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F6: (Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F4: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.62 · Expires 2030-01-01 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-05-20 · Disposition to issuer · Disposed 7,650 · Balance 0 F3: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F6: (Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F4: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.45 · Expires 2031-01-03 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-05-20 · Disposition to issuer · Disposed 7,650 · Balance 0 F3: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F6: (Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F4: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.89 · Expires 2032-01-02 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-05-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F6: (Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F4: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.43 · Expires 2033-01-02 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-05-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F6: (Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F4: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.00 · Expires 2034-01-01 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-05-20 · Disposition to issuer · Disposed 17,500 · Balance 0 F3: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F6: (Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F7: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent.
F2: (Continued from Footnote 1) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding.
F3: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
F4: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
F5: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option.
F6: (Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof.
F7: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2024 Filed May 20, 2024 20:11 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 17,500 | Not disclosed Strike: $19.00 | Not disclosed |
DisclosureSEC source: 0001626199-24-000098 · wk-form4_1716250302.xml · derivative · entry 11 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires 2034-01-01 F3 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F6 · price: (Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F7 · derivative.exercise_date: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| May 20, 2024 Filed May 20, 2024 20:11 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 10,000 | Not disclosed Strike: $7.43 | Not disclosed |
DisclosureSEC source: 0001626199-24-000098 · wk-form4_1716250302.xml · derivative · entry 10 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2033-01-02 F3 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F6 · price: (Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F4 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 20, 2024 20:11 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 10,000 | Not disclosed Strike: $13.89 | Not disclosed |
DisclosureSEC source: 0001626199-24-000098 · wk-form4_1716250302.xml · derivative · entry 9 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2032-01-02 F3 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F6 · price: (Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F4 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 20, 2024 20:11 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 7,650 | Not disclosed Strike: $13.45 | Not disclosed |
DisclosureSEC source: 0001626199-24-000098 · wk-form4_1716250302.xml · derivative · entry 8 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,650 shares Expires 2031-01-03 F3 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F6 · price: (Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F4 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 20, 2024 20:11 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 7,650 | Not disclosed Strike: $3.62 | Not disclosed |
DisclosureSEC source: 0001626199-24-000098 · wk-form4_1716250302.xml · derivative · entry 7 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,650 shares Expires 2030-01-01 F3 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F6 · price: (Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F4 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 20, 2024 20:11 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 7,650 | Not disclosed Strike: $4.09 | Not disclosed |
DisclosureSEC source: 0001626199-24-000098 · wk-form4_1716250302.xml · derivative · entry 6 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,650 shares Expires 2029-01-01 F3 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F6 · price: (Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F4 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 20, 2024 20:11 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 7,650 | Not disclosed Strike: $11.31 | Not disclosed |
DisclosureSEC source: 0001626199-24-000098 · wk-form4_1716250302.xml · derivative · entry 5 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,650 shares Expires 2028-01-01 F3 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F6 · price: (Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F4 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 20, 2024 20:11 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 1,912 | Not disclosed Strike: $61.12 | Not disclosed |
DisclosureSEC source: 0001626199-24-000098 · wk-form4_1716250302.xml · derivative · entry 4 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,912 shares Expires 2025-09-11 F3 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F6 · price: (Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F4 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 20, 2024 20:11 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 3,075 | Not disclosed Strike: $31.08 | Not disclosed |
DisclosureSEC source: 0001626199-24-000098 · wk-form4_1716250302.xml · derivative · entry 3 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,075 shares Expires 2026-09-12 F3 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F6 · price: (Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F4 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 20, 2024 20:11 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 2,868 | Not disclosed Strike: $69.96 | Not disclosed |
DisclosureSEC source: 0001626199-24-000098 · wk-form4_1716250302.xml · derivative · entry 2 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,868 shares Expires 2025-07-16 F3 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F5 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F6 · price: (Continued from Footnote 5) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F4 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 20, 2024 20:11 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001626199-24-000098 · wk-form4_1716250302.xml · nonDerivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Robert E. Conway Rev Trust and Carolyn J. Conway Rev Trust Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2 · price: (Continued from Footnote 1) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:25 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001209191-24-002478 · doc4.xml · derivative · entry 2 CONWAY ROBERT E · CIK 0001184334 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2034-01-30 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 30, 2024, subject to the Reporting Person continuing to provide Continuous Service (as defined in the 2020 Equity Incentive Plan) through such date. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 19:07 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantStock Option (Right to buy) · Derivative | 17,500 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001626199-24-000014 · wk-form4_1704413242.xml · derivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2034-01-01 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 18:56 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantStock Option (Right to buy) · Derivative | 10,000 | $0.00 Strike: $7.43 | $0.00 |
DisclosureSEC source: 0001626199-23-000016 · wf-form4_167296296563582.xml · derivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-01-02 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: 1/12th of the shares subject to the option become vested and exercisable on February 3, 2023 and 1/12 of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 21:20 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001209191-22-061901 · doc4.xml · derivative · entry 2 CONWAY ROBERT E · CIK 0001184334 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2032-12-15 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of December 15, 2022. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 17:31 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantStock Option (Right to buy) · Derivative | 10,000 | $0.00 Strike: $13.89 | $0.00 |
DisclosureSEC source: 0001626199-22-000012 · wf-form4_164133547773725.xml · derivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-01-02 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: 1/12th of the shares subject to the option become vested and exercisable on February 3, 2022 and 1/12th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| September 23, 2021 Filed Sep 24, 2021 18:39 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | SaleCommon Stock | 15,000 | $10.08 | $151,153.50 |
DisclosureSEC source: 0001626199-21-000127 · wf-form4_163252313299208.xml · nonDerivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Robert E. Conway Rev Trust and Carolyn J. Conway Rev Trust Disclosed balance after: 50,000 F1 · price: (1)This transaction was executed in multiple trades at prices ranging from $9.945 to $10.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 23, 2021 Filed Sep 27, 2021 07:02 UTC Amendment | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | PurchaseCommon Stock | 15,000 | $10.08 | $151,153.50 |
DisclosureSEC source: 0001626199-21-000130 · wf-form4a_163274052780471.xml · nonDerivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Robert E. Conway Rev Trust and Carolyn J. Conway Rev Trust Disclosed balance after: 50,000 F1 · kind: The Form 4 filed on September 24, 2021 inadvertently included an incorrect transaction code for the reported transaction. The transaction code included on the original Form 4 was "S" while the correct transaction code should have been "P". F2 · price: This transaction was executed in multiple trades at prices ranging from $9.945 to $10.20. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 21, 2021 Filed Sep 23, 2021 20:31 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | PurchaseCommon Stock | 10,000 | $9.80 | $97,966.00 |
DisclosureSEC source: 0001626199-21-000120 · wf-form4_163244344151145.xml · nonDerivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Robert E. Conway Rev Trust and Carolyn J. Conway Rev Trust Disclosed balance after: 35,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $9.75 to $9.8299. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 12, 2021 Filed May 13, 2021 21:00 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 10,000 | $3.19 | $31,947.00 |
DisclosureSEC source: 0001209191-21-032381 · doc4.xml · nonDerivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $3.18 to $3.20. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 05, 2021 Filed May 6, 2021 20:30 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 10,000 | $3.23 | $32,345.00 |
DisclosureSEC source: 0001209191-21-030629 · doc4.xml · nonDerivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $3.229 to $3.24. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 00:04 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-003468 · doc4.xml · derivative · entry 2 CONWAY ROBERT E · CIK 0001184334 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2031-01-12 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 36 equal monthly installments beginning as of December 21, 2020. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 19:02 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantStock Option (Right to buy) · Derivative | 7,650 | $0.00 Strike: $13.45 | $0.00 |
DisclosureSEC source: 0001626199-21-000018 · wf-form4_160989132098382.xml · derivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,650 Underlying: Common Stock · 7,650 shares Expires 2031-01-03 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: 1/12th of the shares subject to the option become vested and exercisable on February 4, 2021 and 1/12th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 21:15 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 10,000 | $4.16 | $41,630.00 |
DisclosureSEC source: 0001209191-20-064624 · doc4.xml · nonDerivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $4.1497 to $4.1696. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 19, 2020 Filed Nov 23, 2020 17:00 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | PurchaseCommon Stock | 10,000 | $8.03 | $80,300.00 |
DisclosureSEC source: 0000899243-20-031924 · doc4.xml · nonDerivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Robert E. Conway Rev Trust and Carolyn J. Conway Rev Trust Disclosed balance after: 25,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $7.88 to $8.0999. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 25, 2020 Filed Sep 25, 2020 20:20 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 5,000 | $4.28 | $21,399.50 |
DisclosureSEC source: 0001209191-20-052094 · doc4.xml · nonDerivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| September 22, 2020 Filed Sep 24, 2020 20:20 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 3,056 | $4.66 | $14,240.65 |
DisclosureSEC source: 0001209191-20-051890 · doc4.xml · nonDerivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
| September 21, 2020 Filed Sep 21, 2020 21:00 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 10,000 | $4.77 | $47,660.00 |
DisclosureSEC source: 0001209191-20-051302 · doc4.xml · nonDerivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,944 F1 · price: The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $4.743 to $4.80. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 20:01 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantStock Option (Right to buy) · Derivative | 7,650 | $0.00 Strike: $3.62 | $0.00 |
DisclosureSEC source: 0000899243-20-000640 · doc4.xml · derivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,650 Underlying: Common Stock · 7,650 shares Expires 2030-01-01 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2020 and 1/12th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 16:02 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantStock Option (Right to buy) · Derivative | 7,650 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0000899243-19-000500 · doc4.xml · derivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,650 Underlying: Common Stock · 7,650 shares Expires 2029-01-01 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2019 and 1/12th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 22:35 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001209191-18-016698 · doc4.xml · derivative · entry 2 CONWAY ROBERT E · CIK 0001184334 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2028-02-29 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the 2013 Amended and Restated Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 1, 2018. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:18 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantStock Option (Right to buy) · Derivative | 7,650 | $0.00 Strike: $11.31 | $0.00 |
DisclosureSEC source: 0000899243-18-000492 · doc4.xml · derivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,650 Underlying: Common Stock · 7,650 shares Expires 2028-01-01 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: 100% of the shares subject to the option become vested and exercisable on January 2, 2019. Read SEC document |
| July 14, 2017 Filed Jul 17, 2017 20:08 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 10,000 | $2.49 | $24,900.00 |
DisclosureSEC source: 0001209191-17-045336 · doc4.xml · nonDerivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F1 · price: The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $2.475 to $2.55. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 09, 2017 Filed May 10, 2017 14:00 UTC | ALPINE IMMUNE SCIENCES, INC. NVLS · Entity 90802 | PurchaseCommon Stock | 5,000 | $2.34 | $11,700.00 |
DisclosureSEC source: 0001104659-17-031472 · a4.xml · nonDerivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 F1 · price: The price recorded in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.313 to $2.349, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| May 08, 2017 Filed May 11, 2017 12:17 UTC | ALPINE IMMUNE SCIENCES, INC. NVLS · Entity 90802 | PurchaseCommon Stock | 15,000 | $2.28 | $34,200.00 |
DisclosureSEC source: 0001104659-17-031830 · a4.xml · nonDerivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 F1 · price: The price recorded in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.244 to $2.329, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| May 05, 2017 Filed May 9, 2017 14:01 UTC | ALPINE IMMUNE SCIENCES, INC. NVLS · Entity 90802 | PurchaseCommon Stock | 20,000 | $2.30 | $46,000.00 |
DisclosureSEC source: 0001104659-17-031085 · a4.xml · nonDerivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · price: The price recorded in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.262 to $2.338, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| May 04, 2017 Filed May 8, 2017 14:00 UTC | ALPINE IMMUNE SCIENCES, INC. NVLS · Entity 90802 | PurchaseCommon Stock | 10,000 | $2.26 | $22,600.00 |
DisclosureSEC source: 0001104659-17-030597 · a4.xml · nonDerivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · price: The price recorded in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.247 to $2.288, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| March 24, 2017 Filed Mar 27, 2017 20:06 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | PurchaseCommon Stock | 25,000 | $2.59 | $64,750.00 |
DisclosureSEC source: 0001209191-17-022934 · doc4.xml · nonDerivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · price: The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $2.52 to $2.75. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 21:49 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001209191-17-012758 · doc4.xml · derivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2027-02-15 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the 2013 Amended and Restated Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 1, 2017. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested. Read SEC document |
| September 12, 2016 Filed Sep 14, 2016 16:16 UTC | ALPINE IMMUNE SCIENCES, INC. NVLS · Entity 90802 | GrantStock Option (Right to Buy) · Derivative | 12,300 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001104659-16-144631 · a4.xml · derivative · entry 1 CONWAY ROBERT E · CIK 0001184334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,300 Underlying: Common Stock · 12,300 shares Expires 2026-09-12 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: The shares shall vest in 12 equal monthly installments commencing on October 12, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.